{"schema_version":"secwatch.filing_event.v1","accession":"0000950170-22-015746","form_type":"8-K","ticker":"CLSDQ","cik":"0001539029","company_name":"Clearside Biomedical, Inc.","filed_at":"2022-08-09T23:59:59+00:00","discovered_at":"2026-05-14T18:03:56.109428+00:00","generated_at":"2026-06-24T02:00:27.916543+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Clearside reports Q2 loss of $7.8M, secures $65M non-dilutive financing, OASIS data due Nov","bullets":["Net loss $7.8M ($0.13/shr) vs $6.1M ($0.11/shr) in Q2 2021; license revenue $384K down from $780K.","Cash $29.0M at June 30; initial $32.5M royalty payment from HealthCare Royalty extends runway into 2024.","CLS-AX OASIS Phase 1/2a top-line data for all four cohorts expected November 2022.","Non-dilutive financing up to $65M: $32.5M initial, $12.5M escrow, $20M milestone upon XIPERE sales targets.","Appointed Susan L. Coultas, Ph.D., as Chief Clinical Officer; XIPERE J-code effective July 1, 2022."],"urls":{"canonical":"https://secwatch.observer/filing/0000950170-22-015746","json":"https://secwatch.observer/filing/0000950170-22-015746.json","markdown":"https://secwatch.observer/filing/0000950170-22-015746.md","text":"https://secwatch.observer/filing/0000950170-22-015746.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/0000950170-22-015746-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1539029/000095017022015746/clsd-20220809.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-24T02:00:27.916543+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}